Clinical Trial Search

Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Overall Response Rate — 12 Participants — p=0.044

Primary: Maximum Tolerated Dose — 1.8; 1.5 mg/m^2 of Bortezomib

Primary: Maximum Tolerated Dose of Lenalidomide When Given With Obinutuzumab Defined as the Highest Dose Level Have Been Treated With Less Than 2 Instances of Dose Limiting…

Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants

Primary: Percentage of Participants With Response — 23.3 percentage of participants

Primary: Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL — 66.7 Percentage of Participants

Primary: Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance — 14; 13 Participants

Primary: Duration of Exposure to IDELA — 8.1; 7.6; 4.2; 5.1 months

Primary: Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS) — 24.5 percentage of participants

Primary: Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment — 92; 69 percentage of participants

Primary: Progression Free Survival (PFS) Based on Independent Central Review. — 21.5; 13.8; 23.2; 13.8 Months — p=0.000002

Primary: Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1] — 0; 0; 3; 1 participants

Primary: Recommended Phase 2 Dose (RP2D) — 0; 1; 0; 0 Dose Limiting toxicities

Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants

Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Complete Response (CR) Rate — 0; 36 percent of participants

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Overall Response Rate (ORR) — 59.7 percentage of participants — p=<=0.0001

Primary: Percentage of Participants With Objective Response — 92.3 percentage of participants

Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants

Primary: Overall Response Rate — 57.6 percentage of participants — p=< 0.0001

Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants